Compare ECX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECX | DAWN |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | China | United States |
| Employees | 1918 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | ECX | DAWN |
|---|---|---|
| Price | $1.55 | $10.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.11 |
| AVG Volume (30 Days) | ★ 2.7M | 1.8M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $825.35 | $47.48 |
| Revenue Next Year | $35.50 | $31.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $0.76 | $5.64 |
| 52 Week High | $3.25 | $13.20 |
| Indicator | ECX | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 42.37 |
| Support Level | $1.27 | $10.07 |
| Resistance Level | $1.77 | $10.68 |
| Average True Range (ATR) | 0.16 | 0.64 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 9.74 | 9.56 |
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.